The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...

Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

Hormone-regulated immune cells produce IL-10 to resolve pain more effectively in males, offering a potential new target for non-opioid chronic pain treatments.